• Free US shipping for orders above $200
  • Search
  • Cart
Tirzepatide
  • IN-VITRO RESEARCH ONLY — NOT FOR HUMAN USE

Tirzepatide

Price range: £50.00 through £400.00

Tirzepatide is a research‑grade peptide with verified 99% purity, designed for advanced scientific studies in biotechnology and pharmacology. Supplied in precision‑sealed vials, it ensures consistency, reliability, and reproducibility. Strictly intended for laboratory research use only, it empowers scientists to explore innovative peptide pathways.
  • Ships Today if ordered
  • Free international delivery within 1-3 business days on orders over $600, with a tracking number provided.
  • Third party tested
Characteristics
How does Tirzepatide work?
Research
Side Effects
Summary
References
Resource

Characteristics

Name
Tirzepatide (LY3298176), marketed as Mounjaro
Type
Dual incretin receptor agonist (GIP + GLP‑1)
Developer
Eli Lilly
Structure
39‑amino‑acid modified peptide with C20 fatty diacid moiety (enables albumin binding, prolongs half‑life)
Mechanism of Action
Enhances insulin secretion (first & second phase), reduces glucagon levels, improves insulin sensitivity, slows gastric emptying
Administration
Once‑weekly subcutaneous injection
Clinical Outcomes
Demonstrated significant HbA1c reduction and weight loss in Phase 3 SURPASS & SURMOUNT trials
Limitations
Not studied in patients with pancreatitis; not indicated for type 1 diabetes

How does Tirzepatide work?

Tirzepatide works by mimicking the natural hormones GIP (glucose‑dependent insulinotropic polypeptide) and GLP‑1 (glucagon‑like peptide‑1), both of which are incretin hormones that regulate blood sugar and appetite. By activating these two receptors together, Tirzepatide enhances insulin secretion when glucose levels are high, reduces glucagon release, and improves insulin sensitivity in tissues. At the same time, it slows gastric emptying and suppresses appetite, leading to reduced food intake and significant weight loss. The dual action provides stronger metabolic benefits compared to single‑pathway drugs, making Tirzepatide highly effective for both type 2 diabetes management and obesity treatment.

Research

Tirzepatide (LY3298176), marketed as Mounjaro, is a dual incretin receptor agonist developed by Eli Lilly. It activates both GIP (glucose‑dependent insulinotropic polypeptide) and GLP‑1 (glucagon‑like peptide‑1) receptors, providing enhanced glycemic control and significant weight reduction. Clinical evidence from the SURPASS and SURMOUNT trial programs demonstrates superior efficacy compared to existing GLP‑1 agonists, with substantial HbA1c reductions and double‑digit weight loss percentages. The compound’s unique structure—a 39‑amino‑acid peptide conjugated with a C20 fatty diacid—prolongs half‑life through albumin binding, enabling once‑weekly dosing. Regulatory approvals have been granted in the US, EU, and other regions for type 2 diabetes and obesity management. Reported side effects are consistent with incretin therapies, primarily gastrointestinal in nature, and ongoing studies continue to evaluate long‑term safety and cardiovascular outcomes.

Side Effects

Tirzepatide, like other incretin‑based therapies, is most commonly associated with gastrointestinal side effects. Clinical trial participants frequently reported nausea, vomiting, diarrhea, constipation, and abdominal discomfort, especially during dose escalation. Because the drug slows gastric emptying and reduces appetite, some individuals experienced bloating or indigestion. Other reported effects include fatigue, dizziness, and mild headaches. Injection site reactions such as redness or irritation were generally mild and temporary. Rare but important risks include pancreatitis and hypoglycemia, particularly when Tirzepatide is combined with other glucose‑lowering medications. Overall, its side effect profile is consistent with GLP‑1 receptor agonists, but the dual GIP and GLP‑1 mechanism may influence tolerability in certain patients.

Summary

Tirzepatide, marketed under the brand name Mounjaro, is a dual incretin receptor agonist developed by Eli Lilly that targets both GIP (glucose‑dependent insulinotropic polypeptide) and GLP‑1 (glucagon‑like peptide‑1) receptors. Its unique structure—a 39‑amino‑acid peptide conjugated with a C20 fatty diacid—extends its half‑life through albumin binding, allowing for once‑weekly subcutaneous administration. Clinical trials, including the SURPASS and SURMOUNT programs, have demonstrated Tirzepatide’s ability to deliver substantial HbA1c reductions and significant weight loss, often exceeding results seen with single‑pathway GLP‑1 agonists such as semaglutide. Approved for type 2 diabetes and obesity management in multiple regions, Tirzepatide represents a breakthrough in incretin‑based therapy. While its benefits are considerable, the side effect profile is consistent with incretin drugs, most notably gastrointestinal symptoms like nausea, vomiting, and diarrhea, with rare risks such as pancreatitis and hypoglycemia when combined with other glucose‑lowering agents. Overall, Tirzepatide is regarded as a powerful therapeutic option that bridges glycemic control and weight management in modern metabolic research and treatment.

References

Tirzepatide (LY3298176), marketed as Mounjaro, is a dual incretin receptor agonist developed by Eli Lilly. It simultaneously activates GIP (glucose‑dependent insulinotropic polypeptide) and GLP‑1 (glucagon‑like peptide‑1) receptors, offering enhanced glycemic control and significant weight reduction. Evidence from the SURPASS clinical trial program (focused on type 2 diabetes) and the SURMOUNT program (focused on obesity) demonstrates superior efficacy compared to existing GLP‑1 agonists, with substantial HbA1c reductions and double‑digit weight loss percentages. Its unique molecular design—a 39‑amino‑acid peptide conjugated with a C20 fatty diacid—prolongs half‑life through albumin binding, enabling once‑weekly dosing. Regulatory approvals have been granted in the US, EU, and other regions for type 2 diabetes and obesity treatment. Reported side effects are consistent with incretin therapies, primarily gastrointestinal in nature, while ongoing studies continue to evaluate long‑term cardiovascular and safety outcomes.

Resource

Tirzepatide, marketed as Mounjaro, is a dual incretin receptor agonist developed by Eli Lilly that activates both GIP and GLP‑1 receptors. Its unique molecular design allows once‑weekly dosing and has demonstrated remarkable efficacy in clinical trials. The SURPASS program, focused on type 2 diabetes, showed significant HbA1c reductions and improved glycemic control, while the SURMOUNT program, focused on obesity, reported double‑digit weight loss percentages, often exceeding results achieved with single‑pathway GLP‑1 agonists. Regulatory approvals have been granted in the US, EU, and other regions, positioning Tirzepatide as a breakthrough therapy for metabolic disorders. Side effects are consistent with incretin‑based drugs, primarily gastrointestinal issues such as nausea, vomiting, and diarrhea, with rare risks including pancreatitis and hypoglycemia. Overall, Tirzepatide represents a major advancement in metabolic research, bridging effective diabetes management with substantial weight reduction.
SIZE:

5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 100 mg

Reviews

There are no reviews yet.

Be the first to review “Tirzepatide”

Your email address will not be published. Required fields are marked *

Full access
Free for life

Member-only Access

Join to access all Chemists Peptidesresearch products with complete descriptions.
Get Full Access + 20% Discount

Why become a member?

  • Full access to our research peptide catalog.
  • Expert guidance for lab experiments.
  • Free educational resources on peptides.
  • Exclusive discounts on orders.
  • Latest insights via blogs and podcasts.

Your Trusted Partner for High-Quality Research Peptides

Peptide Chemists is more than a supplier of research-grade peptides, providing high-quality compounds that help laboratories achieve precise and reproducible results.

Superior Quality Assurance

Peptide Chemists ensures every peptide meets strict quality and purity standards through rigorous formulation and premium material sourcing.

Independently Validated

All products are tested in-house and by third-party labs, guaranteeing verified purity, concentration, and reliability.

Rapid Delivery & Professional Support

Peptide Chemists provides secure, prompt shipping and expert technical support for accurate and reliable laboratory use.

Scroll to Top